Jensen Investment Management Inc. Has $251.93 Million Holdings in Zoetis Inc. $ZTS

Jensen Investment Management Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 11.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,615,431 shares of the company’s stock after selling 205,972 shares during the quarter. Zoetis makes up approximately 3.0% of Jensen Investment Management Inc.’s holdings, making the stock its 19th biggest holding. Jensen Investment Management Inc. owned about 0.36% of Zoetis worth $251,926,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC acquired a new stake in Zoetis in the first quarter worth $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter worth $29,000. REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC grew its holdings in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ZTS. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Stifel Nicolaus set a $140.00 price target on Zoetis in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Morgan Stanley cut their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. Finally, UBS Group lowered their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and a consensus target price of $180.00.

Zoetis Trading Down 0.3%

ZTS opened at $120.78 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $117.26 and a twelve month high of $181.85. The stock has a market capitalization of $53.23 billion, a price-to-earnings ratio of 20.79, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a 50-day simple moving average of $140.92 and a 200 day simple moving average of $151.47.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is currently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.